Q-omics provides the consensus-scored PRKAR1AP1 profile across patient tissues and cancer cell-line models. PRKAR1AP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRKAR1AP1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, PRKAR1AP1 RNA expression shows 7,351 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where PRKAR1AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKAR1AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKAR1AP1 survival associations across molecular data types. PRKAR1AP1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKAR1AP1 RNA expression–survival associations across cancer types. High PRKAR1AP1 expression shows unfavorable associations in KIRC, UCEC and LUSC, but favorable associations in COAD, KIRP and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for PRKAR1AP1 RNA expression.
This table summarizes PRKAR1AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRKAR1AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKAR1AP1 shows lower tumor expression in LUSC and higher tumor expression in COAD, HNSC, KIRP, LIHC and KIRC. The COAD box plot shows higher PRKAR1AP1 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .010).
This table shows molecular features associated with PRKAR1AP1 in patient tissues and cancer cell lines. In patient samples, PRKAR1AP1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
